Condition: Non Small Cell Lung Cancer · Head and Neck Squamous Cell Carcinoma · Melanoma · Sponsor: CNAO National Center of Oncological Hadrontherapy
Immunotherapy has become the standard of care in different advanced malignancies. Its effectiveness in the palliative setting was demonstrated by several phase III trials. However, the response rate varies according to the cancer under study and to the line of treatment. A potential way to improve the activity of single agent immune checkpoint inhibitors (ICIs) is to enhance the clinical response through further antitumor agents, including radiotherapy. Studies showed that carbon ions may lead to a broader immunogenic response; for their dosimetric characteristics it is possible to reduce integral dose sparing immune cells to direct and sustain a tumor specific immune response. Considering the available preclinical and clinical evidence together, the goal of this study is to explore the feasibility and the clinical activity of adding carbon ion radiotherapy (CIRT), employed with a fractionation strategy comparable to stereotactic body radiation, to ICIs in advanced malignancies where immunotherapy is currently the standard of care.
This description comes directly from the study's public registry record.
Chiara Campo, PhD · +39 0382078407 · campo@cnao.it
Cristina Bono · +39 0382078613 · bono@cnao.it
Always discuss trial participation with your own doctor first.
| GSI Helmholtzzentrum für Schwerionenforschung GmbH | Darmstadt, Germany | Active Not Recruiting |
| Fondazione IRCCS Istituto Nazionale dei Tumori | Milan, Italy | Recruiting |
| National Center for Oncological Hadrontherapy (CNAO) | Pavia, Italy | Not Yet Recruiting |
| Fondazione IRCCS Policlinico San Matteo | Pavia, Italy | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05229614